In the first phase, a prospective cohort study shall be conducted wherein maternal and cord blood samples will be taken after birth and will be sent to the laboratory for measurement of ferritin levels. Study infants will be divided into two groups, Serum Feritin≤75 and Serum Feritin>75 ng/mL. For initial assessment of nervous system development in the auditory pathway, bilateral monaural ABR shall be utilized within the first 48 hours after birth by an audiologist. The test is repeated three times and an average of the waves from two out of three of the tests is used for analysis. The ABR data is analyzed by an audiologist that is unaware of the iron levels. ABR results of the strongest ear, i.e. the ear with lowest latency of wave V in ABR, are utilized in the final analysis. Absolute latencies of waves I, III, and V and inter peak latencies (IPL) I-III, III-V, I-V are recorded as the outcomes indicating neurodevelopment. The second phase of the study will be a clinical trial using the same infants from the first phase of the study. In this phase, infants with Feritin concentrations corresponding to aforementioned definition of Latent Iron Deficiency, i.e. 11-75 ng/mL, will be administered with 1 mg/kg iron drops (ferrous sulfate) from the start of the third week after birth until the end of the infant’s first month of life. At the end of the first month, ABR will be performed again and compared with the initial ABR.